Trials / Not Yet Recruiting
Not Yet RecruitingNCT05175274
Colchicine Use for Primary Prevention of Coronary Artery Disease
Colchicine Use for Primary Prevention in People at High Risk of Coronary Artery Disease
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 6,792 (estimated)
- Sponsor
- Qingdao Central Hospital · Academic / Other
- Sex
- All
- Age
- 40 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Colchicine has been widely used as an anti-gout medicine in the past decades. Some recent clinical trials have proved that low-dose colchicine can be used as a secondary prevention drug for coronary artery disease because of its anti-inflammatory mechanism. However, the effect on primary prevention has not been observed sufficiently. The objective of this study is to determine whether colchicine reduces the incidence of CAD in patients and its safety for long-term use.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Colchicine | Colchicine 0.5mg/tablet |
| DRUG | Placebo | matching placebo |
Timeline
- Start date
- 2022-12-06
- Primary completion
- 2027-03-01
- Completion
- 2028-07-01
- First posted
- 2022-01-03
- Last updated
- 2022-03-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05175274. Inclusion in this directory is not an endorsement.